Id |
Subject |
Object |
Predicate |
Lexical cue |
T25 |
1-2 |
-LRB- |
denotes |
( |
T26 |
2-6 |
NNS |
denotes |
CoVs |
T27 |
6-7 |
-RRB- |
denotes |
) |
T28 |
8-11 |
VBP |
denotes |
are |
T29 |
12-20 |
JJ |
denotes |
zoonotic |
T30 |
21-30 |
NNS |
denotes |
pathogens |
T31 |
31-35 |
IN |
denotes |
with |
T32 |
36-40 |
JJ |
denotes |
high |
T33 |
41-49 |
NN |
denotes |
fatality |
T34 |
50-55 |
NNS |
denotes |
rates |
T35 |
56-59 |
CC |
denotes |
and |
T36 |
60-68 |
JJ |
denotes |
pandemic |
T37 |
69-78 |
NN |
denotes |
potential |
T38 |
80-87 |
NN |
denotes |
Vaccine |
T39 |
88-99 |
NN |
denotes |
development |
T40 |
100-107 |
VBZ |
denotes |
focuses |
T41 |
108-110 |
IN |
denotes |
on |
T42 |
111-114 |
DT |
denotes |
the |
T43 |
115-124 |
JJ |
denotes |
principal |
T44 |
125-131 |
NN |
denotes |
target |
T45 |
132-134 |
IN |
denotes |
of |
T46 |
135-138 |
DT |
denotes |
the |
T47 |
139-151 |
VBG |
denotes |
neutralizing |
T48 |
152-159 |
JJ |
denotes |
humoral |
T49 |
160-166 |
JJ |
denotes |
immune |
T50 |
167-175 |
NN |
denotes |
response |
T51 |
175-176 |
-COMMA- |
denotes |
, |
T52 |
177-180 |
DT |
denotes |
the |
T53 |
181-186 |
NN |
denotes |
spike |
T54 |
187-188 |
-LRB- |
denotes |
( |
T55 |
188-189 |
NN |
denotes |
S |
T56 |
189-190 |
-RRB- |
denotes |
) |
T57 |
191-203 |
NN |
denotes |
glycoprotein |
T58 |
205-216 |
NN |
denotes |
Coronavirus |
T59 |
217-218 |
NN |
denotes |
S |
T60 |
219-227 |
NNS |
denotes |
proteins |
T61 |
228-231 |
VBP |
denotes |
are |
T62 |
232-243 |
RB |
denotes |
extensively |
T63 |
244-256 |
VBN |
denotes |
glycosylated |
T64 |
256-257 |
-COMMA- |
denotes |
, |
T65 |
258-266 |
VBG |
denotes |
encoding |
T66 |
267-273 |
IN |
denotes |
around |
T67 |
274-279 |
CD |
denotes |
66–87 |
T68 |
280-288 |
JJ |
denotes |
N-linked |
T69 |
289-302 |
NN |
denotes |
glycosylation |
T70 |
303-308 |
NNS |
denotes |
sites |
T71 |
309-312 |
IN |
denotes |
per |
T72 |
313-321 |
JJ |
denotes |
trimeric |
T73 |
322-327 |
NN |
denotes |
spike |
R23 |
T26 |
T25 |
arg2Of |
CoVs,( |
R24 |
T27 |
T25 |
arg3Of |
),( |
R26 |
T30 |
T28 |
arg2Of |
pathogens,are |
R27 |
T30 |
T29 |
arg1Of |
pathogens,zoonotic |
R28 |
T30 |
T31 |
arg1Of |
pathogens,with |
R29 |
T35 |
T31 |
arg2Of |
and,with |
R30 |
T34 |
T32 |
arg1Of |
rates,high |
R31 |
T34 |
T33 |
arg1Of |
rates,fatality |
R32 |
T34 |
T35 |
arg1Of |
rates,and |
R33 |
T37 |
T35 |
arg2Of |
potential,and |
R34 |
T37 |
T36 |
arg1Of |
potential,pandemic |
R35 |
T39 |
T38 |
arg1Of |
development,Vaccine |
R36 |
T39 |
T40 |
arg1Of |
development,focuses |
R37 |
T40 |
T41 |
arg1Of |
focuses,on |
R38 |
T44 |
T41 |
arg2Of |
target,on |
R39 |
T44 |
T42 |
arg1Of |
target,the |
R40 |
T44 |
T43 |
arg1Of |
target,principal |
R41 |
T44 |
T45 |
arg1Of |
target,of |
R42 |
T50 |
T45 |
arg2Of |
response,of |
R43 |
T50 |
T46 |
arg1Of |
response,the |
R44 |
T50 |
T47 |
arg1Of |
response,neutralizing |
R45 |
T50 |
T48 |
arg1Of |
response,humoral |
R46 |
T50 |
T49 |
arg1Of |
response,immune |
R47 |
T50 |
T51 |
arg1Of |
response,"," |
R48 |
T57 |
T51 |
arg2Of |
glycoprotein,"," |
R49 |
T57 |
T52 |
arg1Of |
glycoprotein,the |
R50 |
T57 |
T53 |
arg1Of |
glycoprotein,spike |
R51 |
T53 |
T54 |
arg1Of |
spike,( |
R52 |
T55 |
T54 |
arg2Of |
S,( |
R53 |
T56 |
T54 |
arg3Of |
),( |
R54 |
T60 |
T58 |
arg1Of |
proteins,Coronavirus |
R55 |
T60 |
T59 |
arg1Of |
proteins,S |
R56 |
T60 |
T61 |
arg1Of |
proteins,are |
R57 |
T63 |
T61 |
arg2Of |
glycosylated,are |
R58 |
T63 |
T62 |
arg1Of |
glycosylated,extensively |
R59 |
T60 |
T63 |
arg2Of |
proteins,glycosylated |
R60 |
T63 |
T64 |
arg1Of |
glycosylated,"," |
R61 |
T60 |
T65 |
arg1Of |
proteins,encoding |
R62 |
T70 |
T65 |
arg2Of |
sites,encoding |
R63 |
T63 |
T65 |
modOf |
glycosylated,encoding |
R64 |
T70 |
T66 |
arg1Of |
sites,around |
R65 |
T70 |
T67 |
arg1Of |
sites,66–87 |
R66 |
T70 |
T68 |
arg1Of |
sites,N-linked |
R67 |
T70 |
T69 |
arg1Of |
sites,glycosylation |
R68 |
T70 |
T71 |
arg1Of |
sites,per |
R69 |
T73 |
T71 |
arg2Of |
spike,per |
R70 |
T73 |
T72 |
arg1Of |
spike,trimeric |